CNS Oncology最新文献

{"title":"Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review.","authors":"Nina Yu, Osama A Raslan, Han Sung Lee, Brett J Theeler, Tarek A Raafat, Ruben Fragoso, Kiarash Shahlaie, Orwa Aboud","doi":"10.2217/cns-2023-0018","DOIUrl":"10.2217/cns-2023-0018","url":null,"abstract":"<p><p>Craniopharyngiomas are tumors that arise from the remnants of Rathke's pouch along the nasopharynx to the diencephalon. Current standard of care includes maximal surgical resection versus adjuvant radiation if a maximal resection is unfeasible. Pharmacological therapy with MAPK targeted agents is an emerging therapeutic option for tumors with BRAF V600E mutations. We report a 45-year-old male with a strictly third ventricle papillary craniopharyngioma with a BRAF V600E mutation. After initial surgery with subtotal resection, the patient demonstrated durable response to targeted BRAF and MEK inhibitor therapy with vemurafenib and cobimetinib. Our report suggests that targeted therapy may reduce the need for radiation and impact surgical interventions in select cases.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11131344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139721943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment trends in brain metastases from testicular cancer in the United States.","authors":"Joseph Crooks, Matthew Shepard, Rodney E Wegner","doi":"10.2217/cns-2023-0008","DOIUrl":"10.2217/cns-2023-0008","url":null,"abstract":"<p><p><b>Aim:</b> We utilized the National Cancer Database to describe the treatment trends in brain metastases from primary testicular cancers. <b>Methods:</b> We analyzed data from the NCDB from 2010 to 2015 for patients with both primary testicular cancers and brain metastases who were treated with brain-directed radiation. We performed multivariable logistic and cox regressions to identify predictors of treatment type and overall survival respectively. <b>Results:</b> Most patients meeting the above criteria received whole brain radiation therapy as opposed to stereotactic radiosurgery (SRS). Predictors of improved survival were age, private insurance coverage, receipt of chemotherapy, and receipt of SRS. The 5-year survival rate was highest for patients who received SRS. <b>Conclusion:</b> This study confirms significantly improved overall survival with the use of SRS.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10701701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10121356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebral manifestation and diagnostic dilemma of Rosai-Dorfman disease.","authors":"Szintia Almási, Tamás Pancsa, László Tiszlavicz, Anita Sejben","doi":"10.2217/cns-2023-0006","DOIUrl":"10.2217/cns-2023-0006","url":null,"abstract":"<p><p>Rosai-Dorfman disease (RDD) is a rare, S100-positive histiocytic proliferation, that can cause both nodal and extranodal illness. We present a case of a 53-year-old male patient. Magnetic resonance imaging described a plaque-like meningeal lesion, and the preoperative diagnosis was meningioma. Histologically, dense infiltration of lymphocytes, plasma cells, and histiocytes was seen, furthermore, the presence of emperipolesis in the sample was pronounced. In the histiocytes nuclear and cytoplasmic positivity with S100 protein, and nuclear positivity with Cyclin D1 was observed. The case was concluded as RDD. Morphological appearance of intracranial RDD with imaging procedures can present a differential diagnostic challenge. The correct diagnosis is based on the presence of histiocytes with emperipolesis, and properly defined immunohistochemical characteristics.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10701702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9954151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous T-cell lymphoma with CNS involvement: a case series and review of the literature.","authors":"Joshua D Preston, Caroline S Jansen, Siddhartha Kosaraju, Tim Niyogusaba, Tony Z Zhuang, Sally W Iwamoto, Spencer K Hutto, Mary Jo Lechowicz, Pamela B Allen","doi":"10.2217/cns-2023-0014","DOIUrl":"10.2217/cns-2023-0014","url":null,"abstract":"<p><p>Cutaneous T-cell lymphoma (CTCL) is a rare hematologic malignancy that traditionally presents with cutaneous lesions, though metastases are not uncommon in progressive disease. We describe four cases of CTCL with central nervous system (CNS) involvement, detailing the history, pathological characteristics, treatment response, and progression. Median time from initial diagnosis to CNS metastasis was ∼5.4 years (range 3.4-15.5 years) and survival after metastasis was ∼160 days (range 19 days-4.4 years). No patients achieved long-term (>5 years) survival, though some displayed varying degrees of remission following CNS-directed therapy. We conclude that clinicians must be attentive to the development of CNS metastases in patients with CTCL. The growing body of literature on such cases will inform evolving therapeutic guidelines on this rare CTCL complication.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10701703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50157235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-dose bevacizumab for radiation-induced brain necrosis: a case report.","authors":"Emmanouil Panagiotou,&nbsp;Andriani Charpidou,&nbsp;Eleni Fyta,&nbsp;Vasiliki Nikolaidou,&nbsp;Lamprini Stournara,&nbsp;Alexandros Syrigos,&nbsp;Ioannis Gkiozos","doi":"10.2217/cns-2023-0002","DOIUrl":"10.2217/cns-2023-0002","url":null,"abstract":"<p><p>Radiation-induced brain necrosis (RIBN) is a common adverse event from radiation therapy. We present a case of a 56-year-old man, diagnosed with non-small-cell lung cancer with brain metastases 2 years prior, for which he had received whole brain radiotherapy and brain stereotactic radiosurgery, who presented to the oncology unit with headache, dizziness and abnormal gait. MRI of the brain revealed radiological worsening of a cerebellar mass, including edema and mass effect. After a multidisciplinary tumor board meeting, the patient was diagnosed with RIBN and received 4 cycles of high-dose bevacizumab, with complete symptom resolution and significant radiological response. We report the successful use of a high-dose, shorter-duration treatment protocol of bevacizumab for RIBN.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5d/3f/cns-12-98.PMC10410693.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9960507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen.","authors":"Scott A Wu,&nbsp;Dan Tong Jia,&nbsp;Margaret Schwartz,&nbsp;Mary Mulcahy,&nbsp;Kuanghua Guo,&nbsp;Matthew C Tate,&nbsp;Sean Sachdev,&nbsp;Nicolas Kostelecky,&nbsp;David J Escobar,&nbsp;Daniel J Brat,&nbsp;Amy B Heimberger,&nbsp;Rimas V Lukas","doi":"10.2217/cns-2022-0018","DOIUrl":"10.2217/cns-2022-0018","url":null,"abstract":"<p><p><b>Materials & methods:</b> We recently reported the largest trial of breast cancer patients with HER2 positive leptomeningeal metastases (LM) treated with trastuzumab. An additional treatment indication was explored as part of a single institution retrospective case series of HER2 positive esophageal adenocarcinoma LM (n = 2). <b>Results:</b> One patient received intrathecal trastuzumab (80 mg twice weekly) as part of their treatment regimen with durable long-term response and clearance of circulating tumor cells in the cerebral spinal fluid. The other patient demonstrated rapid progression and death as previously described in the literature. <b>Conclusion:</b> Intrathecal trastuzumab is a well-tolerated and reasonable therapeutic option worthy of further exploration for patients with HER2 positive esophageal carcinoma LM. An associative, but not a causal relationship, can be made regarding therapeutic intervention.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2d/66/cns-12-99.PMC10410688.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9960539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS.","authors":"Andy Liu,&nbsp;Huda Alalami,&nbsp;Xuemo Fan,&nbsp;Chirag Patil,&nbsp;Jaya M Gill,&nbsp;Santosh Kesari,&nbsp;Jethro Hu","doi":"10.2217/cns-2022-0021","DOIUrl":"10.2217/cns-2022-0021","url":null,"abstract":"<p><p>Primary T-cell CNS lymphoma is a rare and aggressive malignancy. High-dose methotrexate (MTX) based chemotherapy regimens are used as standard first-line treatment, followed by consolidative strategies to improve the duration of response. Although MTX-based therapy has been shown to be efficacious, treatment options for MTX-refractory disease are not well-defined. Here, we report a case of a 38-year-old man with refractory primary T-cell CNS lymphoma who demonstrated a complete response to pemetrexed treatment. He subsequently received conditioning chemotherapy consisting of thiotepa, busulfan and cyclophosphamide followed by autologous stem cell transplantation. The patient continues to remain recurrence-free to date at 9 years post-treatment.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/de/7a/cns-12-100.PMC10410685.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10024797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report.","authors":"Mason J Webb,&nbsp;William G Breen,&nbsp;Nadia N Laack,&nbsp;Konstantinos Leventakos,&nbsp;Jian L Campian,&nbsp;Ugur Sener","doi":"10.2217/cns-2023-0005","DOIUrl":"10.2217/cns-2023-0005","url":null,"abstract":"<p><p>Leptomeningeal disease (LMD) remains a challenging condition with a dismal prognosis. In this case study, we report partial response of LMD in a patient with metastatic large cell neuroendocrine carcinoma following treatment with proton craniospinal irradiation (CSI), bevacizumab, and pembrolizumab. Two years after the initial diagnosis, he presented with LMD. He underwent proton CSI with bevacizumab followed by combination therapy with pembrolizumab and bevacizumab. He had a partial disease response with progression-free survival after LMD diagnosis of 4.6 months. He unfortunately developed pembrolizumab induced hypophysitis, after which he experienced rapid neurologic clinical progression. Overall, this novel combination led to a durable partial response which warrants prospective evaluation.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/80/b5/cns-12-101.PMC10410687.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10343244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma.","authors":"Garni Barkhoudarian,&nbsp;Michael Badruddoja,&nbsp;Nicholas Blondin,&nbsp;Sajeel Chowdhary,&nbsp;Charles Cobbs,&nbsp;Julius Paul Duic,&nbsp;John Paul Flores,&nbsp;Ekokobe Fonkem,&nbsp;Edward McClay,&nbsp;Louis Burt Nabors,&nbsp;Michael Salacz,&nbsp;Lynn Taylor,&nbsp;Brian Vaillant,&nbsp;Jaya Gill,&nbsp;Santosh Kesari","doi":"10.2217/cns-2022-0016","DOIUrl":"10.2217/cns-2022-0016","url":null,"abstract":"<p><p><b>Aim:</b> The EMulate Therapeutics Voyager™ is a simple, wearable, home-use device that uses an alternating electromagnetic field to alter biologic signaling within cells. <b>Objective:</b> To assess the safety/feasibility of the Voyager in the treatment of recurrent glioblastoma (rGBM). <b>Methods:</b> In this study, patients with rGBM were treated with Voyager as monotherapy or in combination with standard chemotherapy at the Investigator's discretion. Safety was assessed by incidence of adverse events associated with the Voyager. Patients were followed until death. <b>Results:</b> A total of 75 patients were enrolled and treated for at least one day with the Voyager (safety population). Device-related adverse events were uncommon and generally did not result in interruption or withdrawal from treatment. There were no serious adverse events associated with Voyager. A total of 60 patients were treated for at least one month (clinical utility population). The median progression-free survival (PFS) was 17 weeks (4.3 months) in the Voyager only group (n = 24) and 21 weeks (5.3 months) in the Voyager + concurrent therapy group (n = 36). The median overall survival (OS) was 7 months in the Voyager only group and 9 months in the Voyager + concurrent therapy group. In patients treated with Voyager + concurrent therapy, the median OS for patients enrolled with their 1st or 2nd recurrence (n = 26) was 10 months, while in patients enrolled with their 3rd or 4th recurrence (n = 10) OS was 7 months. <b>Conclusion:</b> The data support the safety and feasibility of the Voyager for the treatment of rGBM. Further prospective study of the device is warranted. <b>Trial Registration Number:</b> NCT02296580 (ClinicalTrials.gov).</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/31/ee/cns-12-102.PMC10410686.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10013453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report.","authors":"Ahmad Kh Ibrahimi,&nbsp;Maysa Al-Hussaini,&nbsp;Dima Abu Laban,&nbsp;Rula Ammarin,&nbsp;Lina Wehbeh,&nbsp;Abdelatif Al-Mousa","doi":"10.2217/cns-2023-0004","DOIUrl":"https://doi.org/10.2217/cns-2023-0004","url":null,"abstract":"<p><p>Brain metastasis (BM) from colorectal cancer (CRC) is rare and associated with poor prognosis. The mainstay of treatment for BM from CRC is radiotherapy, systemic treatment options for CRC can include novel targeted agents, conventional chemotherapy or a combination of both. Nevertheless, the efficacy of these systemic treatment options against BM from CRC is not yet fully established. Cetuximab, a monoclonal antibody, has been shown to be effective in patients with <i>KRAS</i> wild-type metastatic CRC. The combination of cetuximab with oxaliplatin-based chemotherapy is commonly utilized as a systemic treatment for metastatic CRC. Hereby, we report a case of BM from CRC with significant response after capecitabine and oxaliplatin (XELOX) combined with cetuximab.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/be/cns-12-97.PMC10171034.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9559580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}